Bullish indicating open at $55-$60, IPO prices at $37
Inozyme Pharma Inc (INZY) stock has reached a 52-week low, trading at $0.77, representing a stark decline from its 52-week high of $7.01. According to InvestingPro analysis, the company, currently valued at $55.25M, faces a tumultuous period in the biopharmaceutical market. This new low reflects a significant downturn for the company, with the stock experiencing a staggering 1-year change of -84.55%. While the company maintains a healthy current ratio of 3.56, InvestingPro analysis reveals concerning trends in cash burn rate and financial health. Investors are closely monitoring INZY as it navigates through these challenges, with analyst price targets ranging from $7 to $23 suggesting potential recovery opportunities. Get access to 11 more exclusive InvestingPro Tips to better understand INZY's financial position.
In other recent news, Inozyme Pharma Inc. reported promising data from its ENERGY 1 trial and Expanded Access Program, which evaluated the investigational drug INZ-701 in infants and young children with ENPP1 Deficiency. The data indicated improvements in survival rates, heart function, and reductions in arterial calcifications, with an 80% survival rate beyond the first year for infants in the study. Inozyme has also completed enrollment for its ENERGY 3 pivotal trial in pediatric patients, with topline data expected in early 2026. Piper Sandler adjusted its price target for Inozyme Pharma to $23 from $30, maintaining an Overweight rating, while H.C. Wainwright reaffirmed a Buy rating with a $16 target, both citing confidence in the potential of INZ-701. Raymond (NSE:RYMD) James reduced its price target to $24 from $26 but maintained an Outperform rating, noting positive interim data and concerns about anti-drug antibodies. The ENERGY 3 study will focus on pyrophosphate levels, with results anticipated in early 2026. Regulatory guidance has been received for a planned ASPIRE pivotal trial for ABCC6 Deficiency, with trial initiation expected in early 2026. These developments reflect Inozyme's ongoing efforts in addressing rare genetic disorders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.